TY - T1的大脑功能连接破坏群体的原发性进行性失语患者(1517)JF -神经学乔-神经学六世- 94 - 15补充SP - 1517 AU - Federica Agosta AU - Elisa Canu盟Michela Leocadi AU -大卫。C首页alderaro盟-朱塞佩·马格纳尼盟Paola Caroppo AU -萨拉Prioni盟卢西奥Tremolizzo盟Ildebrando Appollonio AU - Vincenzo Silani AU -弗拉基米尔Kostic盟Paola Valsasina AU -马西莫菲利皮主持Y1 - 2020/04/14 UR - //www.ez-admanager.com/content/94/15_Supplement/1517.abstract N2 -目的:评估相关的功能连通性模式三种变体原发性进行性失语(PPA)群体的病人。背景:静息状态功能磁共振成像(RS-fMRI)承诺的调查特定脑功能连通性变化相关PPA变体。设计/方法:我们招收了40迟滞型(nfvPPA), 28语义(svPPA)和22 logopenic (lvPPA)变异PPA和62年的年龄,sex-matched健康对照组(HC)。RS-fMRI序列得到从所有参与者,大脑网络感兴趣的是确定使用独立成分分析和组间比较占灰质萎缩(礼物和BPM工具箱,SPM12)。结果:HC相比,所有PPA患者显示减少连接在左后扣带和顶叶皮层在默认模式网络(静)。HC和lvPPA相比,nfvPPA svPPA病人显示:减少连接在左额叶和顶叶脑回,并增加连接在右顶叶在左frontoparietal网络,在两国岛皮质和前扣带内突出网络,在左侧小脑区八世小脑内的网络,并在左前扣带皮层frontostriatal网络。HC相比,lvPPA病人显示增加连接正确的脑岛和丘脑内突出网络。结论:三种PPA变体,静息影响无论潜在的病理。NfvPPA和svPPA病例显示额叶内常见的改变网络反映出他们共同的额颞叶退化。相比其他两个变种,lvPPA显示增加连接在额前地区网络中观察到典型的阿尔茨海默氏症患者。RS-fMRI是强大的改善体内这些临床变异之间的区别。披露:Agosta博士已经收到个人赔偿咨询、担任科学顾问委员会说,或其他活动Idec, Novartis.Dr。Canu没有披露。Leocadi博士没有披露。 Dr. Calderaro has nothing to disclose. Dr. Magnani has nothing to disclose. Dr. Caroppo has nothing to disclose. Dr. Prioni has nothing to disclose. Dr. Lucio has nothing to disclose. Dr. Appollonio has nothing to disclose. Dr. Silani has nothing to disclose. Dr. Kostic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffman-La Roche. Dr. Valsasina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speakers’ honoraria from ExceMed. Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche,Teva Pharmaceutical Industries. ER -